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Abstract
Background Multimorbidity and prolonged use of addictive medications are prevalent among older patients, and known to 
increase the risk of adverse drug events. Yet, the relationship between these two entities has remained understudied.
Aims This study explored the association between multimorbidity burden and prolonged use of addictive medications in geri-
atric patients, adjusted for clinically important covariates. Furthermore, we identified comorbidity patterns in prolonged users.
Methods We conducted a cross-sectional study on a consecutive sample of 246 patients, aged 65–90 years, admitted to a large 
public university hospital in Norway. We defined prolonged use of addictive medications as using benzodiazepines, opioids 
and/or z-hypnotics beyond the duration recommended by clinical guidelines (≥ 4 weeks). Multimorbidity was assessed with 
the Cumulative Illness Rating Scale for Geriatrics (CIRS-G), based on diagnoses made by independent physicians.
Results Compared to non-prolonged use, prolonged use was significantly more common among patients who had psychi-
atric (19/27, 70%), liver (19/22, 86%), upper gastrointestinal tract (21/32, 66%), musculoskeletal (52/96, 54%), or nervous 
system disorders (46/92, 50%). Patients with prolonged use had a higher multimorbidity burden than those without such 
use (CIRS-G score, mean = 7.7, SD = 2.7 versus mean = 4.6, SD = 2.2, p < 0.001). Multivariable logistic regression indi-
cated a significant association between multimorbidity burden and prolonged addictive medication use (OR = 1.72, 95% 
CI 1.42–2.08). Predictive margins postestimation showed a systematic increase in the predicted CIRS-G scores when the 
number of addictive drug used increases.
Conclusions Multimorbidity is strongly associated with prolonged use of addictive medications. Multiple substance use may 
aggravate disease burden of older patients.
Keywords Older patients · Prescription drug overuse · Chronic diseases · Medication safety
Introduction
Medications with abuse liability such as benzodiazepines, 
opioid analgesics, and Z-hypnotics are commonly pre-
scribed for the management of anxiety, pain and insomnia 
[1, 2]. However, due to high-addictive potentials and risk 
of other serious complications (e.g. falls, fractures and 
cognitive impairment), these drugs are listed in various 
medication appropriateness criteria (e.g. NORGEP, Beers 
and STOPP criteria) as potentially inappropriate for older 
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people [3]. Clinical guidelines only recommend short-term 
use (< 4 weeks) [4, 5]. Nonetheless, prolonged use is wide-
spread [6, 7]. In Norway, the prevalence has remained high 
since the past decade. Recent studies revealed high propor-
tions of geriatric patients on persistent and concomitant use 
of addictive medications [8–10].
Multimorbidity, defined as co-occurrence of two or more 
diseases in one person, is also prevalent among older adults 
[11, 12]. Not only is it a predictor of poorer health-related 
quality of life, multimorbidity also increases healthcare uti-
lization, and can be difficult to manage [13]. The presence of 
multiple conditions challenges clinicians to provide tailored 
care and anticipate problems caused by using diverse medi-
cations or treatment forms [14].
Although multimorbidity and prolonged use of addictive 
medications are common in ageing populations, the intersec-
tion between these two entities is poorly understood. Very 
few studies have examined this topic specifically among 
older patients. Also, those conducted generally aimed to 
assess the likelihood of being prescribed potentially addic-
tive medications rather than the effect of multimorbidity 
on prolonged drug use [15, 16]. Moreover, insights regard-
ing diseases that commonly coexist with prolonged use are 
scarce. Addressing these knowledge gaps is important to 
guide future interventions for optimizing health outcomes 
of older people with multiple conditions.
We aimed therefore to explore the relationship between 
multimorbidity burden and prolonged use of addictive medi-
cations in geriatric patients and to identify comorbidity pat-
terns of patients on extended use of such drugs.
Materials and methods
Study design, setting and recruitment
This study was cross-sectional. Participants were recruited 
consecutively between May 2017 and September 2018 from 
the departments of geriatrics, general medicine and neurol-
ogy of a large public university hospital in Norway (Aker-
shus universitetssykehus). The study was open to all patients 
aged between 65 and 90 years, regardless of sociodemo-
graphic background. We did not include patients who were 
critically ill or in palliative treatment (defined by clinicians 
at the medical wards). Exclusion criteria included incapac-
ity to give informed consent (indicated by a Mini-Mental 
State Examination (MMSE) score ≤ 21) [17]; established 
diagnosis of severe depression, dementia or psychotic dis-
orders; severe visual or hearing impairment; and insufficient 
knowledge of the Norwegian language. These criteria were 
predefined and registered prior to the initiation of the study 
(NCT03162081), and generally based on ethical considera-
tions and a wish not to burden very ill patients further and to 
minimize reporting bias. No information on disease profiles 
or medication use was made available to our research team 
prior to and during the recruitment process as this was stored 
in the electronic medical records (EMRs), which could only 
be accessed after obtaining written informed consent from 
the recruited participants.
Study variables and assessment procedure
Main variables
The main variables in this study were prolonged use of 
addictive medications and multimorbidity. We defined 
prolonged use as using benzodiazepines, opioid analgesics 
and/or Z-hypnotics beyond the duration recommended by 
clinical guidelines (≥ 4 consecutive weeks) [4, 5]. Data for 
this variable were collected through reviewing EMRs and 
crosschecked with the patients and referral documents. We 
assessed patients’ multimorbidity using the Cumulative Ill-
ness Rating Scale for Geriatrics (CIRS-G), based on diagno-
ses made by physicians at the medical wards, who were not 
in the research team. The scale contains 14 organ-specific 
categories, showing comorbidity patterns of a patient. Each 
category can be rated from 0 to 4 depending on the severity 
of the conditions diagnosed. Adding up the scores for all 
these categories gives a total CIRS-G score, ranging from 
0 to 56. Higher total CIRS-G scores indicate higher multi-
morbidity burden [18].
Adjustment variables
Based on our previous findings [10], socioeconomic vari-
ables included in the analyses were sex, age (in years), edu-
cational attainment (basic, secondary, and higher education), 
annual income (< 200,000, 200,000–349,000, and ≥ 350,000 
Norwegian krone per year) and living situation (living alone 
versus living with others). Clinical variables comprised pain 
intensity, anxiety and depression symptoms. Pain intensity 
was measured on a 10 cm Visual Analogue Scale (VAS), 
indicating how much pain the respondent is currently feel-
ing. A higher score indicates more intense pain [19]. Anxiety 
and depression symptoms were assessed with the Hospital 
Anxiety and Depression Scale (HADS). HADS has two sub-
scales: anxiety (HADS-A) and depression (HADS-D). Each 
subscale has 7 items and each item is scored from 0 to 3. 
Thus, the total score for each subscale varies between 0 and 
21 [20]. The optimal cutoff value for older patients remains 
to be established. As suggested by Bell et al. (2016), we used 
the total HADS-A/D scores as continuous variables to avoid 
misclassification bias. Higher scores indicate higher levels 
of anxiety and depressive symptoms [21]. Data for these 
variables were collected through questionnaires completed 
by the patients.
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Statistical analysis
Summary statistics (mean, standard deviation (SD); median, 
interquartile range (IQR); and frequency) were used to 
describe characteristics of participants. We assessed dif-
ferences between groups using t test, chi-squared test, and 
Kruskal–Wallis test as appropriate. Bivariable and multivari-
able logistic regression analyses were performed to identify 
associations between the dependent and the explanatory var-
iables. Prolonged use of addictive medications was chosen 
as the outcome variable and multimorbidity burden as the 
main explanatory variable. The strength of the associations 
is presented as odds ratios (OR) and 95% confidence inter-
vals (CI). We also performed bootstrapped sensitivity analy-
sis using 500 replications to confirm the main result. Fur-
thermore, we used predictive margins postestimation (after 
fitting multiple linear regression) to check dose–response 
patterns between the number of addictive drugs and disease 




In total, we approached 665 patients at the medical wards. 
Of these, 346 patients consented to participate whereas 227 
refused the invitation and 92 were precluded due to being 
critically ill or in palliative treatment. Of the 346 patients 
who consented to participate, 100 were excluded based 
on our predefined criteria: aged < 65 or > 90 years (n = 4), 
MMSE score ≤ 21 (n = 49), established diagnosis of severe 
depression, dementia or psychotic disorders (n = 27), severe 
visual or hearing impairment (n = 8), and insufficient knowl-
edge of the Norwegian language (n = 12). We therefore had 
246 eligible participants. The flow of participants through 
the study is shown in Fig. 1.
Comparing characteristics of participants (n = 246) versus 
non-participants (n = 369) showed sex differences. The non-
participant group comprised more males (205/369, 56%) 
than the participant group (109/246, 44%, p = 0.003). The 
two groups did not differ significantly in age (mean = 76.6, 
SD = 7.4 versus mean = 76.6, SD = 6.6, p = 0.09). Partici-
pation rates across the three departments were comparable 
(38.8% geriatrics, 39% general medicine, and 41% neurol-
ogy, p = 0.82). As defined by the responsible ethical com-
mittees in Norway, we had no possibility of obtaining mul-
timorbidity and other clinical data from patients who did not 
consent to participation in the study.
We had complete data for the two main variables (pro-
longed medication use and CIRS-G multimorbidity), medi-
cation groups, age, sex and living situations. The percentages 
of missing data for the remaining variables were: 6% for 
education (14/246), 7% for anxiety, depression and pain 
(17/246), and 16% for income (39/246).
Table 1 shows characteristics of the study sample. Of the 
246 eligible participants, 100 were identified as being on 
prolonged use of addictive medications (≥ 4 consecutive 
weeks). This included 70 patients who exclusively used one 
of the three focussed medication groups (21 opioid users, 7 
benzodiazepine users, and 42 Z-hypnotic users); while 30 
concurrently used several types of these medications. The 
median duration of use for opioids analgesics was 42 weeks 
(IQR = 11–113); while that of for benzodiazepines and 
Z-hypnotics were 51 weeks (IQR = 17–78) and 52 weeks 
(IQR = 15–77), respectively.
Multimorbidity patterns
Figure 2 depicts multimorbidity patterns of patients with 
versus without prolonged use of addictive medications. 
Prolonged use of addictive medications was significantly 
more common among patients diagnosed with psychiatric 
disorders (e.g. anxiety, depression, delirium and person-
ality disorders); and/or morbidity in liver (e.g. hepatitis, 
cirrhosis, cholecystitis and carcinoma), upper gastroin-
testinal tract (e.g. ulcer, dysphagia, bleeding and cancer), 
musculoskeletal (e.g. arthritis, skin infection, melanoma 
and osteoporosis), or nervous systems (e.g. chronic head-
ache, vertigo, Parkinson’s disease and multiple sclerosis). 
Post hoc analyses adjusted for relevant covariates showed 
significant associations between prolonged drug use and 
the presence of the following disease categories: upper 
gastrointestinal tract (OR = 2.78, 95% CI 1.05–7.37), 
liver (OR = 24.62, 95% CI 4.46–135.94), musculoskeletal 
Fig. 1  Flow of participants through the study
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Table 1  Characteristics of the 
study sample
Bold values indicate P value < 0.05
VAS visual analogue scale, SD standard deviation, IQR interquartile range
Items, number (%) unless stated otherwise Prolonged use of addictive medication
No (n = 146) Yes (n = 100) P value
Sex
 Female 71 (52) 66 (48) 0.01
 Male 75 (69) 34 (31)
Age in years, mean (SD) 75 (6.4) 78 (6.5)  < 0.001
Educational attainment
 Basic education 16 (35) 30 (65) 0.001
 Secondary education 64 (67) 31 (33)
 Higher education 58 (64) 33 (36)
Annual income (Norwegian krone)
 < 200,000 8 (38) 13 (62) 0.001
 200 000–349 000 42 (49) 43 (51)
 ≥ 350,000 72 (71) 29 (29)
Living situations
 Living with others 87 (66) 45 (34) 0.03
 Living alone 59 (52) 55 (48)
Hospital anxiety and depression scale (HADS)
 Anxiety score (HADS-A), median (IQR) 4 (1–6) 4 (2–8) 0.17
 Depression score (HADS-D), median (IQR) 3 (1–6) 4 (2–7)  < 0.001
Pain intensity (VAS in centimetres), median (IQR) 0.7 (0.03–2.7) 2.9 (0.5–6.1)  < 0.001
Fig. 2  Multimorbidity patterns
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system (OR = 2.05, 95% CI 1.01–4.22) and nervous system 
(OR = 2.71, % CI 1.27–5.78). More details are shown in 
Online Appendices 1–4.
Multimorbidity burden
The mean score of multimorbidity burden for the study sam-
ple was 5.89 (SD = 2.84).
Patients with prolonged use of addictive medications had 
higher multimorbidity burden than those without such use 
(CIRS-G score mean = 7.70, SD = 2.74 versus Mean = 4.64, 
SD = 2.15, p < 0.001). The burden was comparable for 
those who used only one type versus several types of addic-
tive medications (CIRS-G mean = 7.88, SD = 2.78 ver-
sus Mean = 7.27, SD = 2.65, p = 0.30). Kruskal–Wallis H 
test indicated no significant differences in multimorbidity 
burden between users of the three groups of medications, 
χ2(2) = 0.65, p = 0.72, with a mean rank CIRS-G scores of 
34 for opioid users, 31 for benzodiazepine users and 37 for 
Z-hypnotic users.
Table  2 presents bivariable and multivariable logis-
tic regression models of the associations between the two 
main variables and other covariates. Multimorbidity burden 
was significantly associated with prolonged use of addic-
tive medications (OR = 1.72, 95% CI 1.42–2.08), adjusted 
for sex, age, educational attainment, annual income, living 
situations, pain, anxiety and depression scores. In addition, 
the model showed a significant association between pain 
intensity and prolonged use. Also, compared to those with 
the highest income, patients who earned below 200 000 
NOK/year and 200,000–349,000 NOK/year had higher odds 
for prolonged use of addictive medications. Bootstrapped 
sensitivity analysis yielded consistent results (Online 
Appendix 5). Subsequent multiple linear regression analy-
sis showed a significant relationship between the number of 
addictive drugs used and CIRS-G scores (disease burden), 
β = 1.58 (95% CI 1.00–2.19). Postestimation using predic-
tive margins, as shown in Fig. 3, indicated a systematic 
Table 2  The relationship 
between multimorbidity burden 
and prolonged use of addictive 
medications
Bold values indicate P value < 0.05
VAS visual analogue scale, HADS hospital anxiety and depression scale
Covariates Bivariable models Multivariable model
OR (95% CI) P value Adjusted OR (95% CI) P value
Multimorbidity burden 1.69 (1.46–1.96)  < 0.001 1.72 (1.42–2.08)  < 0.001
Age 1.08 (1.04–1.12)  < 0.001 1.06 (0.99–1.14) 0.09
Sex
 Male (reference)
 Female 2.05 (1.21–3.47) 0.01 1.89 (0.80–4.46) 0.15
Educational attainment
 Basic education (reference)
 Secondary education 0.26 (0.12–0.54)  < 0.001 0.36 (0.11–1.15) 0.08
 Higher education 0.30 (0.14–0.64) 0.002 0.59 (0.18–1.89) 0.37
Annual income (Norwegian krone)
 ≥ 350 000 (reference)
 200,000–349,999 2.54 (1.39–4.66) 0.003 2.60 (1.06–6.37) 0.04
 < 200 000 4.03 (1.51–10.75) 0.01 11.21 (2.33–53.96) 0.003
Living situations
 Living with others (reference)
 Living alone 1.80 (1.08–3.01) 0.03 0.64 (0.25–1.60) 0.34
Anxiety score (HADS-A) 1.07 (0.99–1.15) 0.08 1.05 (0.92–1.21) 0.44
Depression score (HADS-D) 1.16 (1.06–1.26) 0.001 1.03 (0.89–1.19) 0.68
Pain intensity (VAS), per cm 1.25 (1.13–1.38)  < 0.001 1.31 (1.13–1.52)  < 0.001
Fig. 3  Dose–response patterns between the number of addictive 
drugs and disease burden
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increase in disease burden when the number of substances 
used increases. Predicted values of disease burden when the 
number of drugs used were 0, 1, 2 and 3 were 4.97 (95% 
CI 4.53–5.41), 6.56 (95% CI 6.05–7.07), 8.15 (95% CI 
7.13–9.17), and 9.74 (95% CI 8.15–11.33), respectively.
Discussion
We found that patients on prolonged use of addictive 
medications had higher multimorbidity burden, compared 
to those without such use. Most of them had co-diagnosis 
of psychiatric disorders and/or diseases in liver, upper 
gastrointestinal tract, musculoskeletal and integumentary, or 
nervous systems. Higher multimorbidity burden was strongly 
associated with higher odds of being on prolonged use of 
addictive medications, even after controlling for important 
confounders and confirming by sensitivity analysis.
To our knowledge, our study is the first to comprehen-
sively assess comorbid conditions associated with prolonged 
use of prescribed addictive medications in geriatric patients 
across the organ systems. We found that such prolonged use 
coexisted with various specific types of illnesses. This sug-
gests that the effort to detect problematic use of addictive 
medications among older patients should not be limited to 
those with psychiatric disorders, but widened to include also 
other groups of somatic comorbidities as shown. The sig-
nificant relationships between lower income, intense pain 
and prolonged use, found in our study are in accordance 
with previous studies [22, 23]. Socioeconomically disad-
vantaged people might have been exposed to stressful events 
and sleep difficulties, leading to the use of benzodiazepines 
and/or z-drugs [22]. It has been shown that persistent use 
of opioids can cause increased pain intensity (hyperalgesia) 
though actual mechanisms remain unknown [23].
Research in Iceland showed that the majority of those 
who received benzodiazepine and/or Z-hypnotic prescrip-
tions were multimorbid; and that those with multimorbid-
ity were 15 times more likely than those without to be pre-
scribed these drugs [24]. Another recent study focussing on 
older hospitalized patients in San Francisco, also reported 
that patients with higher multimorbidity burden tended 
to receive prescriptions of opioid analgesics at discharge, 
adjusted for sociodemographic variables, and pain [15]. Our 
results corroborate these findings, and also suggest that mul-
timorbidity is not only associated with prescribing but also 
with long-term use of addictive medications. It has been pro-
posed that simultaneously having many diseases may evoke 
feelings of worry, discomfort and sleep disturbances, which 
may lead to the start of opioid analgesics, benzodiazepines 
or Z-hypnotic prescriptions [15, 24]. Hypothetically, the 
progression towards persistent use in geriatric patients with 
multimorbidity may be reinforced by many factors, including 
inappropriate prescribing practices, users’ attitudes, poor 
doctor-patients communications, drug dependence and psy-
chiatric side effects. It is also possible that side effects of 
prolonged use of the drugs may intensify the burden of mul-
timorbidity. To guide clinical practice, future research, espe-
cially longitudinal studies, is encouraged to clarify potential 
causative pathways and dose–response relationship.
Older patients with multimorbidity may have complex 
medication regimens, which can lead to undesirable events 
[25]. Also, excessive use of opioid analgesics and sedative-
hypnotic drugs can cause harm. Feng et al. (2017) explained 
that therapeutic effects and toxicity of opioids can be altered 
when co-medicated with other drugs; and that those metabo-
lized by the cytochrome P450 (CYPs) system tend to be 
associated with drug–drug interactions [26]. Taking ben-
zodiazepines, opioids and/or other central nervous system 
depressant agents simultaneously can also cause overseda-
tion and respiratory failure [27]. Because of age-related 
changes in pharmacodynamics and pharmacokinetics, pro-
longed use of these drugs may be even more problematic for 
older patients with multimorbidity. Pertaining to this issue, 
the National Institute for Health and Care Excellence (NICE) 
guidance recommends establishing patients’ current health 
status and reviewing medicines as critical steps to offer suit-
able care [28]. Furthermore, the Centers for Disease Control 
and Prevention (CDC) guideline for prescribing opioids for 
chronic pain recommends an assessment of benefits versus 
harms of the drugs within the first few weeks [29]. Based 
on these recommendations and our findings, it seems advis-
able that physicians reassess disease burden and screen for 
overuse of addictive drugs among older patients at the latest 
four weeks after initiation.
The strength of this study is that it focussed specially 
on older patients when assessing the relationship between 
multimorbidity and prolonged use of addictive medications. 
Nonetheless, it has some limitations. Using a consecutive 
hospital-based sample limits the generalizability of the study 
findings. However, while random sampling was less practical 
in our situation, we tried to form a sample which was as 
representative as possible through consecutive sampling. 
Moreover, our sample constitutes patients admitted 
to medical wards, regardless of their socioeconomic 
background and for a variety of health problems, and as such 
should be reasonably representative for hospital populations 
of older patients in Scandinavia. Another limitation is the 
use of cross-sectional design, which makes it difficult to 
determine the direction of causality. Thus, the associations 
observed can be bidirectional. In addition, there were many 
patients who refused to participate or who met the exclusion 
criteria. It may be possible that patients with problematic 
use of addictive medications were over-represented among 
those who were not willing to participate. Hence, we 
cannot exclude the possibility that our sample was biased 
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towards milder cases among those admitted to hospital. This 
may also suggest that if the severely ill patients had been 
included, the effect size could have been greater.
Conclusions
Having higher multimorbidity burden increases the odds 
of being on prolonged use of addictive medications, 
or vice versa. Multiple substance use may aggravate 
disease burden of older patients. While opioid analgesics, 
benzodiazepines and Z-hypnotics offer rapid relief, 
evidence for the risks of serious complications associated 
with long-term use is mounting. Thus, to reduce 
susceptibility to adverse drug events for older patients, 
physicians should remain vigilant, and whenever suitable, 
as part of the treatment, also consider removal of drugs 
with possible adverse effects.
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